Marche Polytechnic University

Cristian Massacesi, M.D., Appointed to Replay Board of Directors

Retrieved on: 
Thursday, May 25, 2023

Dr. Massacesi is a leading expert in medical oncology, with over 20 years of research and drug development experience in the pharmaceutical industry.

Key Points: 
  • Dr. Massacesi is a leading expert in medical oncology, with over 20 years of research and drug development experience in the pharmaceutical industry.
  • Prior to that, as Global Clinical Program Head, he led the company’s PI3K-inhibitors portfolio through clinical development, including registrational studies and submissions.
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: “Cristian has an exceptional reputation within the life sciences community and his extensive experience and expertise in leading oncology clinical development programs is a significant addition to Replay’s board.
  • I am excited to be joining as a board member and to be supporting such a strong and dynamic team.

Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis

Retrieved on: 
Tuesday, February 8, 2022

SAN CARLOS, Calif., Feb. 8, 2022 /PRNewswire/ --Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the first worldwide commercial procedures using the RheOx Bronchial Rheoplasty system for the treatment of the symptoms of chronic bronchitis.

Key Points: 
  • SAN CARLOS, Calif., Feb. 8, 2022 /PRNewswire/ --Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the first worldwide commercial procedures using the RheOx Bronchial Rheoplasty system for the treatment of the symptoms of chronic bronchitis.
  • RheOx is a new system that endoscopically delivers non-thermal pulsed electric field (PEF) energy to the lung airways to reduce mucus-producing cells.
  • "The RheOx system is a significant advancement in managing chronic bronchitis patients.
  • RheOx is designed to reduce mucus-producing cells in patients with chronic bronchitis through a minimally invasive bronchoscopic procedure called bronchial rheoplasty.